inosine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Inosine is a nucleoside that is formed when hypoxanthine is attached to a ribose ring (also known as a ribofuranose) via a β-N9-glycosidic bond. It was discovered in 1965 in analysis of RNA transferase. Inosine is commonly found in tRNAs and is essential for proper translation of the genetic code in wobble base pairs.   Wikipedia

Chemistry

  • SMILES: CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3C(=O)NC=Nc23
  • InChIKey: JBVWKTQYMFTKMW-MSQVLRTGSA-N
  • Mol. Mass: 577.72
  • ALogP: -2.27
  • ChEMBL Molecules:
    inosine pranobex  
    inosine  
    inosine pranobex  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

9-beta-d-ribofuranosylhypoxanthine | beta-inosine | hypoxanthine ribonucleoside | hypoxanthine riboside | hypoxanthosine | iad | imunovir | ino | inosina | inosine | inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3) | inosine acedobene dimepranol | inosine pranobex | inosinum | inosiplex | isoprinosin | isoprinosine | methisoprinol | nos | oxiamin | ribonosine

Organizations (33)

Research & Development (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (1)


 

Multiple Sclerosis

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Cholestasis, Intrahepatic (Phase 2/Phase 3)

Cognitive Dysfunction (Phase 3)

COVID-19 (Phase 3)

Diabetic Neuropathies (Phase 3)

Dietary Supplements ()

Head Injuries, Closed (Phase 3)

Healthy Volunteers (Phase 1)

Heart Transplantation (Early Phase 1)

HIV Infections (Phase 4)

Jaundice, Obstructive (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Multiple System Atrophy (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2/Phase 3)

Parkinson Disease (Phase 3)

Pneumonia (Phase 1)

Respiratory Tract Infections (Phase 3)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial Organizations: 33

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue